TABLE 1

Study population

ControlCOPDp-value
Subjects n302302
Female98 (32.5)85 (28.2)0.29
Age years66.2±8.266.3±8.20.99
BMI27.7±4.426.7±6.00.29
Arterial hypertension239 (79.1)231 (76.5)0.49
Dyslipidaemia185 (61.3)185 (61.3)1.00
Diabetes50 (16.6)51 (16.9)1.00
Smoking258 (85.4)259 (85.8)1.00
Family history of CAD45 (14.9)45 (14.9)1.00
PAD22 (7.3)14 (4.6)0.22
CKD (≥3b)4 (1.3)6 (2.0)0.75
ASS180 (59.6)198 (65.6)0.19
Statin150 (49.7)139 (46.0)0.33
Ezetimibe6 (2.0)6 (2.0)1.00
β-blocker89 (29.5)93 (30.8)0.81
ACE inhibitor76 (25.2)97 (32.1)0.07
AT2 channel blocker71 (23.5)59 (19.5)0.20
Calcium channel blocker46 (15.2)44 (14.6)0.82
Diuretic82 (27.2)98 (32.5)0.18
COPD (GOLD) 134 (11.3)
COPD (GOLD) 2120 (39.7)
COPD (GOLD) 398 (32.5)
COPD (GOLD) 450 (16.6)

Data are presented as n (%) or mean±sd, unless otherwise stated. BMI: body mass index; CAD: coronary artery disease; PAD: peripheral artery disease; CKD: chronic kidney disease; ASS: aspirin salicylic acid; ACE: angiotensin-converting enzyme; GOLD: Global Initiative for Chronic Obstructive Lung Disease.